Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Item 1A. RISK FACTORS
Search Results for: ustr
Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in section 1A: 12709
Words on compulsory licenses: 396
ITEM 1A. RISK FACTORS
Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
From Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 1314
Compulsory licensing of patents: 0
Item 1A.RISK FACTORS
Roche’s Risk Management and Compliance site, section on Risk Factors, dated May 2012.
From Roche’s Risk Management and Compliance site, section on Risk Factors, dated May 2012.
Number of words in Risk Factor document: 360
Compulsory licensing of patents: 0
Risk factors
Principal risks and uncertainties
Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
From Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10577
Compulsory licensing of patents: 43
3D. Risk Factors
Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012
From Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96
3.D Risk Factors
GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading
Bristol Myers Squibb’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Bristol Myers Squibb’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item A1: 3605
Compulsory licensing of patents: 27
Item 1A. RISK FACTORS.
Merck 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012
From Merck’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 8038
Compulsory licenses: 44
Item 1A.Risk Factors.
AbbVie’s 10-K Report, section on Risk Factors, for fiscal year ended December 31, 2012
From AbbVie’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 11,093
Compulsory licensing of patents: 88
ITEM 1A. RISK FACTORS